Statement: Patients that are not willing to sign and give written informed consent for participation of the primary trial or the secondary trial will not be made to take part.
Primary_evidence: Inclusion Criteria:   Women >=18 years of age   HER2-negative metastatic breast cancer   Previous adjuvant chemotherapy or hormonal treatment   >=1 measurable target lesion Exclusion Criteria:   Previous treatment with chemotherapy, an anti-angiogenic agent, or a biologic therapy for advanced or metastatic cancer   Radiation therapy within 4 weeks of study treatment start or insufficient recovery from the effects of prior radiation therapy   Central nervous system metastases   Other malignancy within last 5 years, except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix   Serious concurrent infection
Secondary_evidence: Eligibility Criteria:   Patients must be women with a histologically confirmed diagnosis of locally advanced or inflammatory breast carcinoma. Histologic confirmation shall be by either core needle biopsy or incisional biopsy. Punch biopsy is allowed if invasive breast cancer is documented.   Patients must meet one of the criteria defined below (indicate one):   a .Selected Stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0) disease judged primarily unresectable by an experienced breast surgeon; or otherwise deemed appropriate candidates for neoadjuvant treatment.   b. Stage IIIB (T4, Any N, M0) or (Any T, N3, M0) disease.   Physical examination, chest x-ray and any x-rays or scans needed for tumor assessment must be performed within 90 days prior to registration.   Patients with the clinical diagnosis of congestive heart failure or angina pectoris are NOT eligible. Patients with hypertension or age > 60 years must have a Multiple Gated Acquisition (MUGA) or echocardiogram scan performed within 90 days prior to registration (indicate not applicable (NA) if no MUGA required) and Left Ventricular Ejection Fraction (LVEF) % must be greater than the institutional lower limit of normal.   Patients must have a serum creatinine and bilirubin  the institutional upper limit of normal, and an Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic pyruvic transaminase (SGPT)  2x the institutional upper limit of normal. These tests must have been performed within 90 days prior to registration.   Patients must have an Absolute neutrophil count (ANC) of  1,500/μl and a platelet count of  100,000/μl. These tests must have been performed within 90 days prior to registration.   Patients must have a performance status of 0-2 by Zubrod criteria   Pregnant or nursing women may not participate due to the possibility of fetal harm or of harm to nursing infants from this treatment regimen. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. A urine pregnancy test is required for women of childbearing potential.   All patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.